

## 2<sup>nd</sup> Innovation for Cell and Gene Therapies congress 2025, May 22-23, 2025 – Campus Sanofi Gentilly, France

### Abstract Submission Guidelines

In order to provide visibility and promote innovation in the field of Innovation for Cell and Gene Therapies, a call is open for abstract submission for:

- ✓ a 10-minute scientific and technological pitch presentation
- ✓ a poster presented in the Exhibition Hall.

This is a great opportunity for start-ups and academic laboratories to share their new work!

The most successful abstracts will include new breakthrough technologies that can contribute to the research and development of cell and gene therapies.

All submissions must be non-promotional. Abstracts containing commercial products, technologies or services must provide competitive context, and show no commercial bias.

Check out the guidelines and fill-in the Abstract Form and send it to:

Laure Delhon ([laure.delhon@mabdesign.fr](mailto:laure.delhon@mabdesign.fr))

### Evaluation Criteria

**Eligible authors:** Companies or research laboratories that want to share an innovative project, product or technology concerning cell and gene therapies.

**Main topics:** new innovative technologies, products or services in cell and gene therapies.

### Selection criteria

The most successful abstracts will include new breakthrough technologies that can contribute to the research and development of cell and gene therapies. Priority consideration will be given to abstracts that feature:

- ✓ an innovative character of the technology or therapeutic product
- ✓ a health/medical benefit associated
- ✓ a breakthrough research project that offers new ideas and opportunities in the field of ICGT
- ✓ projects that can engage the industrial sector and bring economic benefits
- ✓ Innovation that goes beyond traditional approaches.

## Speaker responsibilities

Each presenter chosen is responsible for all expenses related to his/her participation in the ICGT congress including registration, transportation and accommodation.

By submitting an abstract you grant the organizers permission to publish the abstract in hard copy or in electronic formats.

## Abstract Format

### Abstract Title (Bolded) –Calibri font, size 12

**Title:** The title should clearly define the content of the abstract.

**Author(s):** if concerned include the names of all contributing authors. Underline the speaker's name.

**Author's affiliation:** indicate postal address of the authors.

Example : First author's First Name First author's LAST NAME<sup>1</sup>, Second author's **First name** second author's **LAST NAME<sup>2</sup>**, etc

<sup>1</sup>Department, Organization, Country

<sup>2</sup>Department, Organization, Country

### Abstract (maximum 500 words)

Use only standard keyboard characters. Reduce abbreviations to a minimum, especially non-standard ones, and define at first use. No tables or figures should be inserted into the abstract title or text.

**Font & Size :** Calibri font, size 11

Structure your abstract according to:

- Background:** describe the scientific or/and medical context that lead to your innovation.
- **Offer/project description:** describe your project, research or product. Include in your description its aims, its methodology and its benefits/solutions
- **Innovative strength & Applications:** explain the innovative asset and specificity of your offer from a scientific, medical, technical and economical point of view. Indicate its different applications.
- **Conclusion:** explain how your work contributes to the field of ICGT.

**Keywords:** please provide 5 keywords that describe your presentation, its targets and the goals addressed.

Abstract should be **saved under the Authors Name (FirstName-LastName)** and in .docx format. No other format will be accepted.

**Contact**

For any enquiry please contact Laure Delhon ([laure.delhon@mabdesign.fr](mailto:laure.delhon@mabdesign.fr))